- Home
- CHI vs GYRE Comparison
CHI vs GYRE Comparison
Compare CHI & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- GYRE
- Stock Information
- Founded
- CHI 2002
- GYRE 2002
- Country
- CHI United States
- GYRE United States
- Employees
- CHI N/A
- GYRE N/A
- Industry
- CHI Investment Managers
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- GYRE Health Care
- Exchange
- CHI Nasdaq
- GYRE Nasdaq
- Market Cap
- CHI 820.8M
- GYRE 897.1M
- IPO Year
- CHI N/A
- GYRE N/A
- Fundamental
- Price
- CHI $10.64
- GYRE $8.20
- Analyst Decision
- CHI
- GYRE Strong Buy
- Analyst Count
- CHI 0
- GYRE 1
- Target Price
- CHI N/A
- GYRE $18.00
- AVG Volume (30 Days)
- CHI 186.2K
- GYRE 96.4K
- Earning Date
- CHI 01-01-0001
- GYRE 08-11-2025
- Dividend Yield
- CHI 9.90%
- GYRE N/A
- EPS Growth
- CHI N/A
- GYRE N/A
- EPS
- CHI N/A
- GYRE 0.02
- Revenue
- CHI N/A
- GYRE $102,189,000.00
- Revenue This Year
- CHI N/A
- GYRE $21.04
- Revenue Next Year
- CHI N/A
- GYRE $89.64
- P/E Ratio
- CHI N/A
- GYRE $177.73
- Revenue Growth
- CHI N/A
- GYRE N/A
- 52 Week Low
- CHI $9.70
- GYRE $6.11
- 52 Week High
- CHI $11.61
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CHI 67.50
- GYRE 53.35
- Support Level
- CHI $10.28
- GYRE $7.55
- Resistance Level
- CHI $10.44
- GYRE $8.56
- Average True Range (ATR)
- CHI 0.08
- GYRE 0.51
- MACD
- CHI 0.03
- GYRE 0.01
- Stochastic Oscillator
- CHI 89.74
- GYRE 66.36
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.